IMPROVE-IT
![Countdown to FOURIER: Are very low levels of LDL cholesterol safe?](https://www.pcsk9forum.org/wp-content/uploads/Lansberg-P-150x100.jpg)
Countdown to FOURIER: Are very low levels of LDL cholesterol safe?
A view from PCSK9 Forum Editor Dr Peter Lansberg (Academic Medical Center, Amsterdam, the Netherlands) Comment relates to: Giugliano RP, Wiviott SD, Blazing MA et al. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol A Prespecified Analysis of the IMPROVE-IT…
read more »![IMPROVE-IT: Further reassurance on very low LDL cholesterol](https://www.pcsk9forum.org/wp-content/uploads/derick-raal-146x150.jpg)
IMPROVE-IT: Further reassurance on very low LDL cholesterol
In a pre-specified analysis of IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), patients with LDL cholesterol < 30mg/dL or <0.78 mmol/l after 1 month on treatment had a similar safety profile and fewer cardiovascular events over 6 years than those at higher levels….
read more »![Does the mechanism of lowering LDL cholesterol matter? Insights from recent Mendelian Randomization studies](https://www.pcsk9forum.org/wp-content/uploads/Brian-A-Ference-150x150.jpg)
Does the mechanism of lowering LDL cholesterol matter? Insights from recent Mendelian Randomization studies
Meta-analyses of numerous randomized trials have demonstrated that lowering low density lipoprotein (LDL) cholesterol by inhibiting HMG-CoA reductase (HMGCR) with a statin reduces the risk of major cardiovascular events by approximately 20% for each mmol/L lower LDL cholesterol.1 However, several randomized trials have failed to…
read more »![IMPROVE-IT: Trial data follow through on genetics](https://www.pcsk9forum.org/wp-content/uploads/Hegele-photo-150x112.jpg)
IMPROVE-IT: Trial data follow through on genetics
An ATVB editorial implies that results from IMPROVE-IT could have been predicted by considering genetics data. In a previous report from the Myocardial Infarction Genetics Consortium Investigators,1 carriage of inactivating mutations that attenuate Niemann-Pick C1-like 1 (NPC1L1) function reduced both LDL cholesterol and also protected…
read more »![Enhancing and Improving cardiovascular outcomes](https://www.pcsk9forum.org/wp-content/uploads/TW-picture-104x150.jpg)
Enhancing and Improving cardiovascular outcomes
Implications from IMPROVE-IT: Perspective from Anthony S. Wierzbicki* The link between low density lipoprotein-cholesterol (LDL-C) and cardiovascular disease (CVD) is well established 1 2 . Statins are the first-line drug therapy for the treatment of lipid-associated CVD risk. However the role of second line therapies…
read more »![Latest IMPROVE-IT commentary](https://www.pcsk9forum.org/wp-content/uploads/externalplaceholder-150x150.jpg)
Latest IMPROVE-IT commentary
read more »![IMPROVE-IT: will it prove anything?](https://www.pcsk9forum.org/wp-content/uploads/TW-picture-104x150.jpg)
IMPROVE-IT: will it prove anything?
Professor Anthony S. Wierzbicki, London UK Comments on the IMPROVE-IT debate Cardiovascular disease (CVD) guidelines are emphasising the use of clinical outcome data on major vascular events (American Heart Association/American College of Cardiology)1 or hard CVD events alone (UK NICE)2 . They have begun to…
read more »